Cargando…
Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab
AIM: Multiple studies have revealed the correlation between gut microbiome and the response to checkpoint inhibitors (CPIs) in patients with cancer, and oral administration of butyrate‐producing enterobacteria has been reported to enhance the efficacy of CPIs. However, the effects of enterobacteria...
Autores principales: | Nouso, Kazuhiro, Shiota, Shohei, Fujita, Rio, Wakuta, Akiko, Kariyama, Kazuya, Hiraoka, Atsushi, Atsukawa, Masanori, Tani, Joji, Tada, Toshifumi, Nakamura, Shinichiro, Tajiri, Kazuto, Kaibori, Masaki, Hirooka, Masashi, Itobayashi, Ei, Kakizaki, Satoru, Naganuma, Atsushi, Ishikawa, Toru, Hatanaka, Takeshi, Fukunishi, Shinya, Tsuji, Kunihiko, Kawata, Kazuhito, Takaguchi, Koichi, Tsutsui, Akemi, Ogawa, Chikara, Ochi, Hironori, Yata, Yutaka, Kuroda, Hidekatsu, Iijima, Hiroko, Matono, Tomomitsu, Shimada, Noritomo, Yasuda, Satoshi, Toyoda, Hidenori, Kumada, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523959/ https://www.ncbi.nlm.nih.gov/pubmed/37563961 http://dx.doi.org/10.1002/cam4.6416 |
Ejemplares similares
-
Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study
por: Tanaka, Kazunari, et al.
Publicado: (2023) -
Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
por: Tada, Toshifumi, et al.
Publicado: (2022) -
Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2022) -
New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study
por: Tada, Toshifumi, et al.
Publicado: (2022) -
The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis
por: Hatanaka, Takeshi, et al.
Publicado: (2022)